Progress on New Vaccine Strategies for the Immunotherapy and Prevention of Cancer

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2004 Jun 3

PMID 15173875

Citations 71

Authors

Jay A Berzofsky

Masaki Terabe

SangKon Oh

Igor M Belyakov

Jeffrey D Ahlers

John E Janik

John C Morris

Affiliations

Soon will be listed here.

Abstract

In recent years, great strides in understanding and regulating the immune system have led to new hope for harnessing its exquisite specificity to destroy cancer cells without affecting normal tissues. This review examines the fundamental immunologic advances and the novel vaccine strategies arising from these advances, as well as the early clinical trials studying new approaches to treat or prevent cancer.

Citing Articles

Neoantigen Identification and Dendritic Cell-Based Vaccines for Lung Cancer Immunotherapy.

Kumari K, Singh A, Chaudhary A, Singh R, Shanker A, Kumar V Vaccines (Basel). 2024; 12(5).

PMID: 38793749 PMC: 11125796. DOI: 10.3390/vaccines12050498.

Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.

Ali K, Nabeel M, Mohsin F, Iqtedar M, Islam M, Rasool M Med Oncol. 2024; 41(5):112.

PMID: 38592510 DOI: 10.1007/s12032-024-02347-z.

Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases.

Kurilin V, Alshevskaya A, Sennikov S Biomedicines. 2024; 12(3).

PMID: 38540312 PMC: 10968364. DOI: 10.3390/biomedicines12030699.

The Apoptotic Potential Activity of Terminalia Brownii Extracts against Various Cancer Cell Lines.

Alfaifi M, Alqasem Z Asian Pac J Cancer Prev. 2023; 24(8):2629-2639.

PMID: 37642048 PMC: 10685225. DOI: 10.31557/APJCP.2023.24.8.2629.

Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses.

Huang M, Nicholson L, Batich K, Swartz A, Kopin D, Wellford S J Clin Invest. 2019; 130(2):774-788.

PMID: 31661470 PMC: 6994156. DOI: 10.1172/JCI128267.

References

Zeh 3rd H, Dudley M, Rosenberg S, Yang J . High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol. 1999; 162(2):989-94. View

Antonia S, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo M . Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol. 2002; 167(5):1995-2000. View

Conry R, Curiel D, Strong T, Moore S, Allen K, Barlow D . Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res. 2002; 8(9):2782-7. View

Liso A, Stockerl-Goldstein K, Auffermann-Gretzinger S, Benike C, Reichardt V, van Beckhoven A . Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2000; 6(6):621-7. DOI: 10.1016/s1083-8791(00)70027-9. View

Paglia P, Chiodoni C, Rodolfo M, Colombo M . Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med. 1996; 183(1):317-22. PMC: 2192419. DOI: 10.1084/jem.183.1.317. View

Thornton A, Shevach E . Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol. 1999; 164(1):183-90. DOI: 10.4049/jimmunol.164.1.183. View

Traversari C, van der Bruggen P, Luescher I, Lurquin C, Chomez P, Van Pel A . A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992; 176(5):1453-7. PMC: 2119413. DOI: 10.1084/jem.176.5.1453. View

Rosenzwajg M, Jourquin F, Tailleux L, Gluckman J . CD40 ligation and phagocytosis differently affect the differentiation of monocytes into dendritic cells. J Leukoc Biol. 2002; 72(6):1180-9. View

Schaed S, Klimek V, Panageas K, Musselli C, Butterworth L, Hwu W . T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res. 2002; 8(5):967-72. View

10.

Lee K, Chuang E, Griffin M, Khattri R, Hong D, Zhang W . Molecular basis of T cell inactivation by CTLA-4. Science. 1998; 282(5397):2263-6. DOI: 10.1126/science.282.5397.2263. View

11.

Terabe M, Berzofsky J . Immunoregulatory T cells in tumor immunity. Curr Opin Immunol. 2004; 16(2):157-62. DOI: 10.1016/j.coi.2004.01.010. View

12.

Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola F . Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J Natl Cancer Inst. 2002; 94(11):805-18. DOI: 10.1093/jnci/94.11.805. View

13.

Nair S, Snyder D, Rouse B, Gilboa E . Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer. 1997; 70(6):706-15. DOI: 10.1002/(sici)1097-0215(19970317)70:6<706::aid-ijc13>3.0.co;2-7. View

14.

Banchereau J, Palucka A, Dhodapkar M, Burkeholder S, Taquet N, Rolland A . Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001; 61(17):6451-8. View

15.

Oh S, Hodge J, Ahlers J, Burke D, Schlom J, Berzofsky J . Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol. 2003; 170(5):2523-30. DOI: 10.4049/jimmunol.170.5.2523. View

16.

Terabe M, Matsui S, Park J, Mamura M, Noben-Trauth N, Donaldson D . Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med. 2003; 198(11):1741-52. PMC: 2194133. DOI: 10.1084/jem.20022227. View

17.

Ahlers J, Belyakov I, Thomas E, Berzofsky J . High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J Clin Invest. 2001; 108(11):1677-85. PMC: 200990. DOI: 10.1172/JCI13463. View

18.

Simons J, Mikhak B, Chang J, DeMarzo A, Carducci M, Lim M . Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999; 59(20):5160-8. View

19.

Janssen E, Lemmens E, Wolfe T, Christen U, von Herrath M, Schoenberger S . CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003; 421(6925):852-6. DOI: 10.1038/nature01441. View

20.

Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger J . Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998; 95(22):13141-6. PMC: 23738. DOI: 10.1073/pnas.95.22.13141. View